Mineralys Therapeutics Analyst Ratings
Mineralys Therapeutics Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/08/2023 | 196% | Credit Suisse | $38 → $37 | Maintains | Outperform |
| 05/16/2023 | 204% | Credit Suisse | → $38 | Reiterates | Outperform → Outperform |
| 03/16/2023 | 204% | Credit Suisse | $40 → $38 | Maintains | Outperform |
| 03/07/2023 | — | Evercore ISI Group | Initiates Coverage On | → Outperform | |
| 03/07/2023 | 116% | Wells Fargo | → $27 | Initiates Coverage On | → Overweight |
| 03/07/2023 | 220% | Credit Suisse | → $40 | Initiates Coverage On | → Outperform |
| 03/07/2023 | 156% | Guggenheim | → $32 | Initiates Coverage On | → Buy |
| 03/07/2023 | 212% | B of A Securities | → $39 | Initiates Coverage On | → Buy |
| 03/07/2023 | 260% | Stifel | → $45 | Initiates Coverage On | → Buy |
| 日期 | 上行/下行 | 分析公司 | 目標價格變動 | 評級變動 | 之前/當前的評級 |
|---|---|---|---|---|---|
| 08/08/2023 | 196% | 瑞士信貸 | 38 美元 → 37 美元 | 維護 | 跑贏大盤 |
| 05/16/2023 | 204% | 瑞士信貸 | → 38 美元 | 重申 | 跑贏大盤 → 跑贏大盤 |
| 03/16/2023 | 204% | 瑞士信貸 | 40 美元 → 38 美元 | 維護 | 跑贏大盤 |
| 03/07/2023 | — | Evercore ISI 集團 | 啓動覆蓋開啓 | → 跑贏大盤 | |
| 03/07/2023 | 116% | 富國銀行 | → 27 美元 | 啓動覆蓋開啓 | → 超重 |
| 03/07/2023 | 220% | 瑞士信貸 | → 40 美元 | 啓動覆蓋開啓 | → 跑贏大盤 |
| 03/07/2023 | 156% | 古根海姆 | → 32 美元 | 啓動覆蓋開啓 | → 購買 |
| 03/07/2023 | 212% | B of A 證券 | → 39 美元 | 啓動覆蓋開啓 | → 購買 |
| 03/07/2023 | 260% | Stifel | → 45 美元 | 啓動覆蓋開啓 | → 購買 |
What is the target price for Mineralys Therapeutics (MLYS)?
Mineralys Therapeutics（MLYS）的目標價格是多少？
The latest price target for Mineralys Therapeutics (NASDAQ: MLYS) was reported by Credit Suisse on August 8, 2023. The analyst firm set a price target for $37.00 expecting MLYS to rise to within 12 months (a possible 196.00% upside). 9 analyst firms have reported ratings in the last year.
瑞士信貸於2023年8月8日公佈了Mineralys Therapeutics（納斯達克股票代碼：MLYS）的最新目標股價。這家分析公司將目標股價定爲37.00美元，預計MLYS將在12個月內升至12個月內（可能上漲196.00％）。去年有9家分析公司公佈了評級。
What is the most recent analyst rating for Mineralys Therapeutics (MLYS)?
分析師對Mineralys Therapeutics（MLYS）的最新評級是多少？
The latest analyst rating for Mineralys Therapeutics (NASDAQ: MLYS) was provided by Credit Suisse, and Mineralys Therapeutics maintained their outperform rating.
Mineralys Therapeutics（納斯達克股票代碼：MLYS）的最新分析師評級由瑞士信貸提供，Mineralys Therapeutics維持其表現跑贏大盤的評級。
When is the next analyst rating going to be posted or updated for Mineralys Therapeutics (MLYS)?
Mineralys Therapeutics（MLYS）的下一個分析師評級何時公佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Mineralys Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Mineralys Therapeutics was filed on August 8, 2023 so you should expect the next rating to be made available sometime around August 8, 2024.
分析師在進行了廣泛的研究後得出了股票評級，其中包括瀏覽公開財務報表，與Mineralys Therapeutics的高管和客戶交談，以及聽取業績電話會議。大多數分析師每三個月進行一次評級，因此每家公司每年應該獲得4個評級。Mineralys Therapeutics的最新評級是在2023年8月8日提交的，因此你應該預計下一個評級將在2024年8月8日左右公佈。
Is the Analyst Rating Mineralys Therapeutics (MLYS) correct?
分析師對 Mineralys Therapeutics (MLYS) 的評級正確嗎？
While ratings are subjective and will change, the latest Mineralys Therapeutics (MLYS) rating was a maintained with a price target of $38.00 to $37.00. The current price Mineralys Therapeutics (MLYS) is trading at is $12.50, which is out of the analyst's predicted range.
儘管評級是主觀的，將會發生變化，但最新的Mineralys Therapeutics（MLYS）評級維持不變，目標股價爲38.00美元至37.00美元。Mineralys Therapeutics（MLYS）目前的交易價格爲12.50美元，超出了分析師的預測區間。
譯文內容由第三人軟體翻譯。